The
Journal of Philosophy, Science & Law
Volume
8, April 14, 2008
www.miami.edu/ethics/jpsl
A Guide to Biotechnology
Law and Business*
By Robert A. Bohrer
Reviewed by
Lawrence
M. Sung, J.D., Ph.D.**
* Carolina Academic
Press,
Durham
,
NC
, 2007, 332 pages.
**
Law
School
Professor and Intellectual Property Law Program Director,
University
of
Maryland
School
of
Law
;
Partner, Dewey & LeBoeuf LLP.
Perhaps
the most challenging final examination question I have experienced was through
during my undergraduate astronomy course where the professor asked, “Describe
the origins of the universe. Be brief.” Such a task demands a complicated
dynamic of content and expression that applies aptly to the endeavor to address
the legal and business aspects of biotechnology in a comprehensive, yet
detailed, manner. However, Professor Bohrer successfully earns a high mark with his effort. Beyond the substance, he offers
a clear, well-written work.
According
to the author, the book seeks to provide a “big picture” overview of
biotechnology law and business by setting forth a practical and integrated
discussion of the issues that face biotechnology product developers.
Furthermore, the book anticipates a readership that includes intellectual
property (IP), Food & Drug Administration (FDA), and business lawyers, as
well as biotechnology executives seeking a concise introduction to the
fundamental topics. The text begins with a presentation of the definition and
basics of biotechnology. At the outset, Professor Bohrer delivers a nice review of the essential science that is easily accessible to
the lay reader. Moreover, he begins with
a consideration of the how the science feeds the commercial enterprise to
establish the industry.
This
interplay continues logically with the explanation of the role of technology
transfer from academic institutions to biotechnology companies. In this
chapter, Professor Bohrer describes the Bayh-Dole Act and its facilitation of a symbiosis between
academic research and commercial development. In this regard, he teaches an
esoteric subject in plain language masterfully. This discussion is arguably the
highlight of this book and serves to distinguish the book from other written
works that have purported to explain technology transfer in the biotechnology
field.
The
next section of the book considers the legal governance of biotechnology
through the procurement and enforcement of IP, particularly patent, rights as
well as FDA regulation of biotechnology products and processes. Nested in this
section are also two chapters on the start-up of a biotechnology company and
the complexities of financing the venture. Once again, Professor Bohrer reveals his experience and excellent insights into
the business aspects of biotechnology. These chapters are also must-reads.
If
there is a weaker aspect of this book, it rests with the treatment in Chapter 4
of biotechnology patent rights. The overview properly acknowledges the
statutory framework and the operative standards, but falls somewhat short in
recognizing and articulating the highly nuanced nature of the scope of patent
claims and its implications for the patentability and enforceability of
biotechnology inventions in the maintenance of true marketplace exclusivity.
Notably absent is a discussion of the impact of the patent infringement
exemption of the 35 U.S.C. § 271(e)(1) safe harbor and of the effect on
biotechnology inventions of the process patent infringement provisions under 35
U.S.C. § 271(g).
Another
concern is a bit more holistic. In the physical sciences, a researcher can
dedicate her life work to climbing the highest mountain and be confident that
on the day she summits, she will have seen all there is to see. In the
biological sciences, by contrast, upon the summit only then does a researcher
see that indeed in the distance there are even greater mountains she never
before knew existed. This inherent complexity with living systems defies true
characterization when viewed through a single lens. In turn, the ethical,
social and legal implications of the biological sciences face problems in
convention and in the design of meaningful governing principles. In other
words, because the nomenclature and our understanding of the science are
subject to change, the governance of such science must also be capable of
change. But, at least with the law, the guiding hand of the controlling weight
of precedent based on the rule of stare decisis resists paradigmatic shifts. Therein lies the problem – and moreover,
conundrums can give rise to legal unpredictability, which is the bane of
commercial enterprise.
The
book, of course, is also not immune to fast changing standards. In the time
since the book’s publication, several significant patent law decisions of the
U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have
issued that will have a profound impact on the patent rights associated with
biotechnology inventions, principally in the doctrines of inherent anticipation
and obviousness. Furthermore, the pending patent reform legislation before the
U.S. Congress and the rule change proposals by the U.S. Patent & Trademark
Office to streamline its administrative examination functions may have adverse
effects on the ability to obtain and enforce biotechnology patent rights.
Nevertheless,
the establishment of a common frame of reference is a critical starting point
in evolving an understanding of the field. In this regard, Professor Bohrer starts the reader off in the right direction. But
because the patent rights play such a significant role in the creation of
investment backed expectations about biotechnology, further guideposts (and
possibly alerts of traps for the unwary) would be instructive. In addition, the
reader would be helped by information about the increasing role that contracts
play in the biotechnology industry as mechanisms to govern research and
commercial behavior outside of the default, traditional IP rights doctrines.
For example, many reagents and other research tool suppliers are relying upon
conditional sales or product-associated licenses that restrict researcher uses
to certain purposes in ways not readily apparent to, or heeded by, the
consumers, particularly academic researchers.
The
FDA regulatory discussion provides a good overview of the federal regulatory
scheme that pertains to drugs, biologics, and devices. Perhaps because of a
distinction between biotechnology products and pharmaceuticals that the author
might have drawn, there is little, if any, indication of the pervasive (and
economically overwhelming) litigation between brand name drug and generic drug
manufacturers that arise under the Hatch-Waxman Act based upon the filing of an
Abbreviated New Drug Application with the FDA. While not all biotechnology
companies or their affairs might be engaged in such contentious matters
directly, many experience collateral investment and market effects based on
their relationships with brand name drug manufacturers (“Big Pharma”).
The
remainder of the book addresses the ethical considerations surrounding
biotechnology and includes a particular discussion of human gene therapy
issues. There is a mention, albeit brief, of the ethical issues that are raised
in the context of human embryonic stem cell technology. Lastly, a brief
introduction to products liability concerns that attach to biotechnology is
included. The recent (February 2008) decision of the U.S. Supreme Court, in Riegel v. Medtronic, that a plaintiff may not
sue under state law to challenge the safety or effectiveness of a medical
device to which the FDA has given premarket approval will surely also have some
future effect on tort liability involving biotechnology products.
In
summary, Professor Bohrer’s book is a highly
recommended resource for the library of anyone interested in understanding the
biotechnology industry from a practical, non-historical, perspective. The
discussions about the commercialization of biotechnology products and processes
through academic technology transfer and start-up establishment and financing
are especially strong. The book also provides a solid foundation on the aspects
of IP rights, FDA regulation, and ethical implications of biotechnology. In
these latter regards, however, the book would best assist the reader’s
understanding of the biotechnology industry as a starting point for further
learning about the complex interdisciplinary interactions that frame the
commercial enterprise, only a small part to which the general public is privy
through other media outlets.